Stay updated on Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial
Sign up to get notified when there's something new on the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page.

Latest updates to the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new site revision (v3.4.2) was added and an old government funding notice was removed; these are site-wide UI updates and do not affect study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedAdded a site-wide notice about a lapse in government funding, with references to cc.nih.gov and opm.gov, and updated the record revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedThe page now displays the study as Active, not recruiting and uses color-coded highlights to show additions and deletions; it also notes the 2026-01-22 revision (v3.4.0) and updates sections such as Contacts/Locations, Study Status, and Study Design.SummaryDifference0.8%

- Check42 days agoChange DetectedThe page footer shows a revision update, adding 'Revision: v3.3.4' and removing 'Revision: v3.3.3'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedFooter updates include adding Revision: v3.3.3 and removing HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.1%

- Check85 days agoChange DetectedFooter Revision updated from v3.3.1 to v3.3.2; no other page content changes detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page.